RxDoctor Payments Data

Tabitha Matthews

Nurse Practitioner · Kansas City, MONPI 1447986047

Payments from drug & device makers

$1,018in general payments, 2019–2025

Across 25 payments — averaging $40.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$530
  • Astellas Pharma US Inc$169
  • Genmab U.S., Inc.$112
  • GSK$41
  • ADC Therapeutics America, Inc.$36
  • AstraZeneca$28
  • plus $103 from 5 others

What the payments were for

  • Food & beverage$72671%
  • Education$29229%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,018 in reported general payments places this provider in the 75th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$44,876
Medicare patients
193
Services billed
803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib83$1,127,265
ImbruvicaIbrutinib72$1,000,983
CalquenceAcalabrutinib Maleate61$883,658
JaypircaPirtobrutinib29$564,790
VenclextaVenetoclax40$495,359
RevlimidLenalidomide14$259,603
PromactaEltrombopag Olamine11$146,957
Acyclovir72$2,501
Fluconazole15$707
Ondansetron Hcl47$696
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim54$480
Dapsone11$458
Dexamethasone21$199
Pantoprazole Sodium12$192
Gabapentin11$186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$28$883,65861 claims
AbbVieVenclexta$530$495,35940 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →